Li Jie (Jerry) Wang
About Li Jie (Jerry) Wang
Li Jie (Jerry) Wang is the Associate Director of Process Biology at Sonoma Biotherapeutics, where he has worked since 2021. He has extensive experience in cell therapeutic program development and has held various research positions at notable institutions.
Work at Sonoma Biotherapeutics
Li Jie (Jerry) Wang serves as the Associate Director of Process Biology at Sonoma Biotherapeutics, a position he has held since 2021. Based in Seattle, Washington, he leads interdisciplinary teams focused on the development of process and assay methodologies. His role emphasizes the genetic and molecular characterization of cell products, utilizing lentiviral and gene editing platforms. His contributions are integral to advancing cell therapeutic program development within the organization.
Previous Experience in Biotechnology
Before joining Sonoma Biotherapeutics, Wang worked at Synthego Corporation as a Senior Scientist in Preclinical research from 2019 to 2020. He also held the position of Research Scientist IV and Supervisor at Seattle Children's Research Institute from 2016 to 2019. His earlier roles include Research Associate at The Scripps Research Institute - Scripps Florida from 2014 to 2015 and a Postdoctoral Research Fellow at Fred Hutchinson Cancer Research Center from 2015 to 2016. Wang's diverse experience spans various aspects of biotechnology and research.
Educational Background and Postdoctoral Training
Li Jie (Jerry) Wang completed his postdoctoral training at Chang Gung University from 2012 to 2014. Following this, he continued his research as a Postdoctoral Research Fellow at Fred Hutchinson Cancer Research Center from 2015 to 2016. His educational background and postdoctoral experiences have equipped him with a strong foundation in cell therapeutic program development and advanced research methodologies.
Specialization in Cell Therapeutics
Wang specializes in the genetic and molecular characterization of cell products. His expertise includes the use of lentiviral and gene editing platforms, which are critical in the field of cell therapeutics. This specialization supports his leadership in developing innovative processes and assays at Sonoma Biotherapeutics, contributing to the advancement of therapeutic solutions.